DRI Healthcare (TSE:DHT.UN) has released an update.
DRI Healthcare Trust has expanded its investment in rare disease therapies by acquiring an additional royalty interest in Xenpozyme, the sole approved treatment for Acid Sphingomyelinase Deficiency (ASMD), from HLS Therapeutics Inc. for up to $45.75 million. This strategic move increases the Trust’s committed capital to over $1 billion since its IPO and extends its portfolio duration, promising long-term value for unitholders. The Trust now holds approximately a 1% royalty on global Xenpozyme sales, with its first receipt expected in Q2 2025.
For further insights into TSE:DHT.UN stock, check out TipRanks’ Stock Analysis page.
